Esperion Therapeutics Inc. (ESPR) 已与Athyrium基金达成一项新的财务安排。根据协议条款，Athyrium基金将有权获得基于Esperion公司净销售额的分层特许权使用费，费率区间为12%至33%。此外，Athyrium基金还将有资格获得一系列的里程碑付款。这些财务收益将持续累积，直至Athyrium基金实现其初始投资2.0倍的回报总额。
Esperion Therapeutics Inc. (ESPR) 已与Athyrium基金达成一项新的财务安排。根据协议条款，Athyrium基金将有权获得基于Esperion公司净销售额的分层特许权使用费，费率区间为12%至33%。此外，Athyrium基金还将有资格获得一系列的里程碑付款。这些财务收益将持续累积，直至Athyrium基金实现其初始投资2.0倍的回报总额。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.